Tryptase detection in bone-marrow blood: A new diagnostic tool in systemic mastocytosis

Proelss, Julia; Wenzel, Joerg; Ko, Yon; Bieber, Thomas; Bauer, R.

doi:10.1016/j.jaad.2006.09.020

Cited by 15 publications

(8 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, recent studies show that the serum tryptase level positively correlates with the severity category of SM [16], [17]. As shown in Table 1, there was no significant difference between the OPA score according to the presence of an elevated (≥20 ng/mL) serum tryptase level.…”

Section: Resultsmentioning

confidence: 80%

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis

et al. 2008

View full text Add to dashboard Cite

BackgroundIndolent forms of mastocytosis account for more than 90% of all cases, but the types and type and severity of symptoms and their impact on the quality of life have not been well studied. We therefore performed a case-control cohort study to examine self-reported disability and impact of symptoms on the quality of life in patients with mastocytosis.Methodology/Principal FindingsIn 2004, 363 mastocytosis patients and 90 controls in France were asked to rate to their overall disability (OPA score) and the severity of 38 individual symptoms. The latter was used to calculate a composite score (AFIRMM score). Of the 363 respondents, 262 were part of an ongoing pathophysiological study so that the following data were available: World Health Organization classification, standard measures of physical and psychological disability, existence of the D816V KIT mutation, and serum tryptase level. The mean OPA and AFIRMM scores and the standard measures of disability indicated that most mastocytosis patients suffer from disabilities due to the disease. Surprisingly, the patient's measurable and perceived disabilities did not differ according to disease classification or presence or absence of the D816V KIT mutation or an elevated (≥20 ng/mL) serum tryptase level. Also, 32 of the 38 AFIRMM symptoms were more common in patients than controls, but there were not substantial differences according to disease classification, presence of the D816V mutation, or the serum tryptase level.ConclusionsOn the basis of these results and for the purposes of treatment, we propose that mastocytosis be first classified as aggressive or indolent and that indolent mastocytosis then be categorized according to the severity of patients' perceived symptoms and their impact on the quality of life. In addition, it appears that mastocytosis patients suffer from more symptoms and greater disability than previously thought, that mastocytosis may therefore be under-diagnosed, and that the symptoms of the indolent forms of mastocytosis might be due more to systemic release of mediators than mast cell burden.

show abstract

Section: Resultsmentioning

confidence: 80%

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Total tryptase is elevated in the case of sufficiently severe systemic anaphylaxis but is also correlated with total MC burden, especially in mastocytosis [10,12]. Elevated BT has been detected in various other haematologic disorders, particularly in myeloproliferative and myelodysplastic disorders and has also been reported in patients with haemodialysis end-stage kidney disease [23] and in cutaneous mastocytosis with extensive and diffuse lesions [12,[24][25][26]. A persistently elevated tryptase level is recommended by the World Health Organization as a minor criterion in the diagnostic evaluation of systemic mastocytosis after exclusion of these other conditions [14,15].…”

Section: Discussionmentioning

confidence: 99%

Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase

Potier

Lavigne

Chappard

et al. 2009

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Proelss et al [13] have suggested that measurement of tryptase in bone marrow aspirate (BMA) could be useful for the diagnosis of SM. Measurement of tryptase produced by mast cells in BMA evaluates the presence of an excessive mast cell load outside the biopsied area, as the substance concerned is present initially at a high concentration in the marrow before being distributed to the general circulation.…”

Section: Introductionmentioning

confidence: 99%

Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis

Livideanu

Apoil²,

Lepage

et al. 2015

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Tryptase detection in bone-marrow blood: A new diagnostic tool in systemic mastocytosis

Cited by 15 publications

References 24 publications

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis

Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase

Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis

Contact Info

Product

Resources

About